Business Wire

NY-GENESIS

27.1.2022 15:02:10 CET | Business Wire | Press release

Share
Genesis Q4 Report Highlights Key Trends from 2021 in Crypto Lending, Trading and Custody

Genesis , a digital asset industry pioneer and digital currency prime brokerage, today released its Q4 2021 Market Observations Report, which provides detail on the company’s growth over the past quarter and the whole year. This growth highlights major trends across institutional digital asset markets, including the continued diversification of digital asset investments, the deepening sophistication of institutional investors entering the crypto market, new types of institutions participating in the market, increasing allocations from managers of diversified portfolios and the growing need for multi-service institutional prime brokerages.

Q4 2021 marked Genesis’ strongest quarter to date, with approximately $102 billion in transactional volume, cementing a year of significant growth across all of its business lines. Highlights during the quarter across crypto lending, trading and custody include the following:

  • Loan originations reached $50 billion, up 40% over Q3 2021. Loan originations for 2021 totaled $131 billion, nearly 7x higher than 2020.
  • Spot trading volume totaled $30.8 billion, up 23% from Q3. For the full year 2021, Genesis’ spot trading volumes increased nearly 6x over 2020 to $116.5 billion.
  • Derivatives notional volume traded was $20.7 billion during the quarter, an increase of 62% compared with Q3. Total notional value traded for the year grew to $53.8 billion, more than 9x over 2020.
  • Onboarded Custody clients grew 53% from the previous quarter.
  • Genesis’ headcount expanded 22% during the quarter to reach 170 employees, spread across three continents.

“2021 was a pivotal year for the crypto industry, and one that demonstrated the merits of smart tactical trading around a core position,” said Michael Moro, CEO of Genesis. “As this asset class continues to mature, driven by increasing institutional participation and growing regulatory clarity, we believe that taking a comprehensive approach to portfolio management will only become more important, and we look forward to achieving new milestones on behalf of our clients in 2022.”

Crypto Lending

Genesis’ lending desk remains the largest crypto lender in the industry and finished the year with over $150 billion in cumulative originations since its launch in March of 2018. Genesis executed a record $50 billion in new originations in Q4 alone, a 40% increase from the previous quarter, and marked the desk’s fifteenth consecutive quarter of growth. Active loans outstanding climbed to $12.5 billion to close the quarter, up 12.3% from Q3. Loans outstanding peaked at over $16 billion in mid-November before seeing a wave of year-end deleveraging as prices on most cryptocurrencies fell.

Over the quarter, the lending desk saw that while demand from clients engaging with DeFi platforms is still strong, focus has shifted towards layer-1 (L1) alternatives, resulting in slightly higher originations in those coins.

Derivatives and Spot Trading

Genesis saw another record quarter in derivatives trading activity with $20.7 billion in notional value traded globally, a 62% quarter-on-quarter growth and a 360% increase over Genesis’ results in Q4 2020. This brings trading activity for 2021 to $53.8 billion in notional volume, an 812% increase over 2020. In December, Genesis also printed the first ever ETH Micro futures trade on the CME and was #1 in market share for blocked BTC and ETH exchange-cleared options via Paradigm, with over $1.5 billion traded.

The Genesis spot desk traded $30.8 billion in volume in Q4, delivering the second-best quarter in the desk’s long history, as well as an increase of 23% over the prior quarter and a 279% increase over Q4 of 2020. Total spot trading volume for the year reached $116.5 billion, a 463% increase over 2020.

Custody

Genesis Custody closed 2021 with a 53% increase in the number of customers onboarded from Q3. The business also reached two critical milestones during Q4 一 Genesis Custody was approved by the Financial Conduct Authority (FCA) as a cryptoasset business, signifying its strong controls, governance and compliance frameworks to counter financial crime, and it completed the System and Organization Controls (SOC) 2 Type 1 examination.

Over the course of Q4, Genesis Custody also began staking assets for clients. The business has taken steps to continue to expand its portfolio of services offered, and to better integrate custody into its clients’ trading and portfolio management workflows.

The Genesis Q4 2021 Market Observations Report provides a comprehensive look into key market activity through insights from the firm’s spot trading, derivatives trading, lending, custody, treasury and prime brokerage businesses. To read the full Q4 2021 Market Observations Report, click here .

About Genesis

Genesis is a full-service digital currency prime brokerage providing a single point of access for select qualified individuals and global institutional investors. Genesis combines unrivaled operational excellence, a seamless user experience, and best-in-class client service to provide the full suite of services global investors require to manage their digital asset portfolios.

The firm offers sophisticated market participants a fully integrated platform to trade, borrow, lend, and custody digital assets, creating new opportunities for yield while increasing capital efficiency for counterparties.

Genesis is a wholly owned subsidiary of Digital Currency Group (DCG) , one of the largest private investors in blockchain and digital asset companies.

For more information on Genesis, please visit genesistrading.com and follow @GenesisTrading on Twitter.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye